The FDA has also issued a new warning about a long-acting osteoporosis drug called Reclast. This medication is injected once a year to strengthen bones and prevent fractures. The FDA has received two dozen reports of serious kidney problems associated with Reclast. The agency advises against using this drug in patients with kidney problems and warns doctors to make sure that patients are properly hydrated before getting the infusion. Kidney function should be monitored both before and after giving Reclast.
Join Over 130,000 Subscribers at The People's Pharmacy
Each week we send two free email newsletters with breaking health news, prescription drug information, home remedies and a preview of our award-winning radio show. Join our mailing list and get the information you need to make confident choices about your health.